COMMUNIQUÉS West-GlobeNewswire

Annual General Meeting 2024 – GN Store Nord A/S
13/03/2024
Today, GN Store Nord A/S held its Annual General Meeting. The Annual General Meeting was held in accordance with the agenda announced on February 19, 2024, as set out below. The report by the Board of Directors was [...]
Spectral AI Schedules 2023 Fourth Quarter and Full Year Financial Results and Conference Call
13/03/2024
DALLAS, March 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
13/03/2024
MALVERN, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and [...]
3Daughters Announces Three New Appointments to Board of Directors
13/03/2024
Board will help advance the mission and support development of our game-changing IUD for contraception (3D-001) MANSFIELD, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- 3Daughters , a clinical development company fueling [...]
Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual Meeting
13/03/2024
New shared service contract expands the unmatched clinical results achieved with IG-SRT to a broader base of prospective customers Active traffic at the Company’s booth generated a record-high number of sales leads and [...]
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
13/03/2024
Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8 ® for the treatment of ALS with the objective of submitting an NDA in 2024 Released long-term data from the open-label extension of the [...]
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
13/03/2024
Preclinical research published in Vaccines demonstrates Infectimune ® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants Patent for composition of matter and [...]
HealthLynked Welcomes David Rosal as New Chief Financial Officer
13/03/2024
NAPLES, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. ( OTCQB: HLYK ), a pioneering provider of healthcare network and services, is delighted to announce the appointment of David Rosal as its [...]
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
13/03/2024
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the [...]
STRATA Skin Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
13/03/2024
HORSHAM, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative [...]
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
13/03/2024
Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund. Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adjunctive therapy to insulin, for the [...]
Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting
13/03/2024
SYDNEY, Australia, March 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced a poster presentation [...]
IMUNON Files IND Application to Begin Human Testing of IMNN-101
13/03/2024
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2 The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA LAWRENCEVILLE, N.J., March [...]
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
13/03/2024
International Society for Cell & Gene Therapy (ISCT) Names Dr. Lowdell with the Career Achievement Award in Cell and Gene Therapy Recognizing Exceptional Contributions and Achievements in the Field Boca Raton, [...]
MIMEDX Introduces E-Commerce and Account Management Platform
13/03/2024
Designed to Streamline Ordering, Payment Processing, and Reimbursement Submissions MARIETTA, Ga., March 13, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the [...]
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
13/03/2024
New pharmacokinetic data demonstrate Virtue ® SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without polymer degradation or detectable remaining polymer within 90 [...]
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
13/03/2024
Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024 Preliminary data from ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and [...]
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
13/03/2024
PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT CHAIN [...]
AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune
13/03/2024
COMMUNIQUÉ DE PRESSE DE NOUVELLES RECHERCHES MONTRENT QUE LE MASITINIB LIMITE LES DOMMAGES NEURONAUX DANS UN MODÈLE DE MALADIE NEURODÉGÉNÉRATIVE D'ORIGINE NEUROIMMUNE C'EST LA PREMIÈRE FOIS QUE LE MASITINIB DÉMONTRE SA [...]

Pages